Pembrolizumab/talimogene laherparepvec

Pembrolizumab/talimogene laherparepvec Reactions 1704, p305 - 2 Jun 2018 Pembrolizumab/talimogene laherparepvec Nephritis, fever and chills: case report A 68-year-old man developed immune-mediated nephritis following treatment with pembrolizumab and fever and chills following treatment with talimogene laherparepvec [routes and dosages not stated]. The man had lentigo maligna melanoma of the scalp for which he was started on treatment with pembrolizumab. Following three doses of pembrolizumab, he developed grade 3 immune-mediated nephritis. The man was then treated with prolonged steroid course. Later, he was started on treatment with intratumoral talimogene laherparepvec therapy to address local disease progression in the setting of recent immune-mediated adverse events. Talimogene laherparepvec was administered according to standard dosing guidelines. He tolerated the therapy well except he developed low-grade fevers and chills after initial treatment, that resolved with acetaminophen premedication [durations of treatment to reactions onset not stated; not all outcomes stated]. Author comment: "Given concern for true progression, pembrolizumab was initiated. After 3 doses, he had grade 3 immune-mediated nephritis requiring a prolonged steroid course." "Overall, the patient tolerated [talimogene laherparepvec] well, reporting low-grade fevers and chills after initial treatment, which resolved with acetaminophen premedication." Rizzo JM, et al. Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy. JAAD Case Reports 4: 379-381, No. 4, May 2018. Available from: URL: http://doi.org/10.1016/ j.jdcr.2018.01.023 - USA 803323243 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Pembrolizumab/talimogene laherparepvec

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/pembrolizumab-talimogene-laherparepvec-ZxuDMMgVMw
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46948-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p305 - 2 Jun 2018 Pembrolizumab/talimogene laherparepvec Nephritis, fever and chills: case report A 68-year-old man developed immune-mediated nephritis following treatment with pembrolizumab and fever and chills following treatment with talimogene laherparepvec [routes and dosages not stated]. The man had lentigo maligna melanoma of the scalp for which he was started on treatment with pembrolizumab. Following three doses of pembrolizumab, he developed grade 3 immune-mediated nephritis. The man was then treated with prolonged steroid course. Later, he was started on treatment with intratumoral talimogene laherparepvec therapy to address local disease progression in the setting of recent immune-mediated adverse events. Talimogene laherparepvec was administered according to standard dosing guidelines. He tolerated the therapy well except he developed low-grade fevers and chills after initial treatment, that resolved with acetaminophen premedication [durations of treatment to reactions onset not stated; not all outcomes stated]. Author comment: "Given concern for true progression, pembrolizumab was initiated. After 3 doses, he had grade 3 immune-mediated nephritis requiring a prolonged steroid course." "Overall, the patient tolerated [talimogene laherparepvec] well, reporting low-grade fevers and chills after initial treatment, which resolved with acetaminophen premedication." Rizzo JM, et al. Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy. JAAD Case Reports 4: 379-381, No. 4, May 2018. Available from: URL: http://doi.org/10.1016/ j.jdcr.2018.01.023 - USA 803323243 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off